Visit other SMART + STRONG sites:
AIDSMEDSREAL HEALTHTU SALUD
Subscribe to:
POZ magazine
E-newsletters
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


September 30, 2008
Once-Daily Prezista as Good as Twice-Daily Dose for Some
Once-daily Norvir (ritonavir)-boosted Prezista (darunavir) is as effective as standard twice-daily dosing for some treatment-experienced patients, according to a study published in the October issue of the Journal of Acquired Immune Deficiency Syndromes
September 29, 2008
Anti-Obesity Meds May Also Have Anti-HIV Benefits
Anti-obesity medications may be a new weapon in the arsenal to fight HIV, according to laboratory findings published in the October issue of Nature Biotechnology.
September 26, 2008
Zetia Reduces LDL in People Living With HIV
Zetia (ezetimibe) may be an effective option for HIV-positive patients who had moderately elevated low-density lipoprotein (LDL) levels—the “bad” form of cholesterol—and were on antiretroviral therapy (ARV), based on a small clinical trial reported in the October 15 issue of Clinical Infectious Diseases.
September 25, 2008
Tropism Testing May Help Predict Disease Progression
Tropism testing, which detects the presence of HIV that uses the CXCR4 (X4) coreceptor, is currently used to determines whether a patient may be able to use Pfizer’s entry inhibitor Selzentry (maraviroc). Now, a new study indicates that the test may also pinpoint a greater risk of AIDS-related health problems, even in people with high CD4 cell counts who are not yet on treatment—and may even help guide when to start or switch antiretroviral (ARV) therapy.
September 24, 2008
HIV Treatment Diminishes Non-AIDS Illnesses
Antiretroviral (ARV) therapy significantly decreases the risk of non-AIDS-related illnesses in people with CD4 counts below 350, according to a study published in the October 15 issue of Clinical Infectious Diseases and reported by aidsmap.com.
September 23, 2008
Twice-Daily Retrovir Now OK for Kids
Retrovir (zidovudine) may now be used twice daily in HIV-positive children ages six weeks to 18 years and can be dosed by weight, according to an announcement by the United States Food and Drug Administration (FDA).
Nipple Shield Filters HIV From Breast Milk
A British chemical engineer has designed a thin nipple shield that he claims can filter HIV out of the breast milk of HIV-positive mothers, according to a report by the BBC News.
September 22, 2008
Relocation of Gut Bacteria Linked to Low CD4s
In some people living with HIV, bacteria normally contained within intestinal lymph nodes are relocated to the blood stream. This process is associated with a lack of increase in CD4 cells —even in people whose HIV viral load is undetectable—according to a study in the October 1 issue of AIDS.
September 19, 2008
Why Some Primates Aren’t Vulnerable to SIV
Scientists have discovered key biological differences that may explain why some primates don’t get sick despite being infected with simian immunodeficiency virus (SIV)—a virus almost identical to HIV—according to a Nature Medicine study reported by Science Daily.
September 18, 2008
New Maturation Inhibitor Enters Phase 2 Testing
Vivecon (MPC-9055), a new maturation inhibitor, is moving into early Phase 2 studies. The experimental antiretroviral will be studied in HIV-positive people to determine the proper dose of the drug, according to a press release from Myriad Genetics.
September 17, 2008
Chamomile May Help Prevent Diabetes and Its Complications
Properties in chamomile, including a tea made from the flower, have a number of anti-diabetes effects in rats, according to new findings published in the Journal of Agricultural and Food Chemistry by researchers in the United Kingdom and Japan.
September 16, 2008
Birth Defect Screening Just as Reliable in Positive Pregnant Women
Screening for fetal abnormalities is accurate for pregnant women living with HIV and should be offered, similar to recommendations for HIV-negative women, according to the authors of a Swiss study reported in the October 1 issue of AIDS.
September 15, 2008
Acyclovir Also Fights HIV in People With Herpes
A team of researchers has identified how the anti-herpes drug acyclovir (Zovirax) limits HIV replication in people coinfected with herpes simplex virus (HSV), according to a report published in the September 11 issue of Cell Host & Microbe
September 12, 2008
People Now Able to Stay on First Antiretroviral Regimens Longer
People living with HIV are now able to remain on a first antiretroviral (ARV) regimen—which now usually includes once daily dosing and fewer pills—for much longer than people taking older twice-daily, multiple pill regimens, according to the authors of a study published in the October 1 issue of AIDS.
HIV Stigma Hinders Access to Care and Prevention
The stigma surrounding HIV has kept people infected with the virus in the Arkansas delta region from coming forward for health services, including antiretroviral treatment, according to a panelist at a meeting earlier this month in Little Rock and was reported on by the Arkansas Democrat Gazette.
September 11, 2008
HIV Status Unknown for Most “Negative” Men Online
Seventeen percent of HIV-positive men who have sex with men (MSM) and nearly three quarters of MSM who’ve never been tested for HIV say they are HIV negative in their online profiles, according to a study published in the September issue of the Journal of Urban Health.
September 10, 2008
Further Possible Benefits of PrEP
Intermittent use of Truvada (tenofovir plus emtricitabine) by an HIV-negative gay man who had multiple instances of unprotected anal sex didn’t prevent him from becoming infected, but did appear to help preserve a strong immune response to the virus.
September 09, 2008
High Rate of Circumcision Side Effects in Kenyan Survey
Male circumcision may be associated with a lower risk of HIV infection in clinical trials, but the results of a survey involving 1,007 boys and young men in Kenya describe its high rates of side effects in a real-world setting as “shocking” and “unacceptable.”
September 08, 2008
Researchers Link Gene to Key Antibody Responses
A powerful gene controls the production of antibodies that effectively neutralize human retroviruses such as HIV, according to new laboratory research conducted by scientists at UCSF and NIAID. This may explain why most humans who are infected with HIV do not make neutralizing antibodies that successfully fight the virus.
September 05, 2008
PAD Common in HIV-Positive Patients Over 50
Peripheral arterial disease (PAD) was found in just over 10 percent of a group of HIV-positive patients older than 50, according to the authors of a study published in the September issue of AIDS Research and Human Retroviruses.
September 04, 2008
Genes, Not Race, Should Guide Antiretroviral Treatment
A person’s genetic sequence, and not his or her race, should guide scientists and health care providers in the design of clinical trials and treatment decisions with antiretroviral (ARV) drugs such as efavirenz (found in Sustiva and Atripla), according to a review article published in the September 1 issue of AIDS.
September 03, 2008
Vistide Not Effective in Treating PML
The addition of Vistide (cidofovir) to antiretroviral (ARV) therapy did not slow disease progression or prevent death in HIV-positive people with progressive multifocal leukoencephalopathy (PML), according to a study in the September 1 issue of AIDS.
September 02, 2008
Norvir and Heart Conduction Disturbances
People taking 400 mg or more of Norvir (ritonavir) twice-daily may have delayed conduction of electrical charges in their hearts, according to a notice from the U.S. Food and Drug Administration (FDA) detailing revisions to Norvir’s prescribing information.
Worsening Depression in Four Patients on Isentress
Four patients who switched to a regimen containing Isentress (raltegravir) had a temporary worsening of preexisting depression, according to a letter in the September 12 issue of AIDS that was reported by aidsmap.com.
Web Exclusives

Run This Town

A Voice Against HIV, Malaria and TB

Therapeutic Vaccines: Steady Wins the Race

» More

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

10 Years Ago In POZ


More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Community
Advocacy
Job Listings
Events Calendar
Starting Treatment
My Cool Tools


    deltasct
    Palo Alto
    California


    whilboy
    Los Angeles
    California


    avgcaguy
    Fresno
    California


    usagineko
    st. louis and columbia
    Missouri
Click here to join POZ Personals!
Talk to Us
Poll
Question: Do young people see the HIV/AIDS epidemic as a serious threat?
Yes
No

Survey
It's A Girl Thing

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2009 Smart + Strong. All Rights Reserved. Terms of use and Your privacy